Nexpoint Asset Management’s Heron Therapeutics HRTX Stock Holding History

Nexpoint Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203K	Hold	475,750	–	–	0.01%	67
2026 Q1	$381K	Hold	475,750	–	–	0.03%	79
2025 Q4	$618K	Hold	475,750	–	–	0.04%	76
2025 Q3	$599K	Hold	475,750	–	–	0.05%	83
2025 Q2	$985K	Hold	475,750	–	–	0.09%	59
2025 Q1	$1.05M	Hold	475,750	–	–	0.09%	54
2024 Q4	$728K	Hold	475,750	–	–	0.08%	50
2024 Q3	$947K	Hold	475,750	–	–	0.11%	53
2024 Q2	$1.67M	Hold	475,750	–	–	0.22%	40
2024 Q1	$1.32M	Hold	475,750	–	–	0.2%	44
2023 Q4	$809K	Sell	475,750 -23,381	-5%	-$25.7K	0.12%	39
2023 Q3	$514K	Hold	499,131	–	–	0.07%	50
2023 Q2	$579K	Hold	499,131	–	–	0.08%	55
2023 Q1	$754K	Hold	499,131	–	–	0.08%	47
2022 Q4	$1.25M	Hold	499,131	–	–	0.1%	57
2022 Q3	$2.11M	Hold	499,131	–	–	0.14%	69
2022 Q2	$1.39M	Hold	499,131	–	–	0.12%	69
2022 Q1	$2.85M	Hold	499,131	–	–	0.37%	37
2021 Q4	$4.56M	Hold	499,131	–	–	0.64%	28
2021 Q3	$5.34M	Hold	499,131	–	–	0.92%	25
2021 Q2	$7.75M	Sell	499,131 -110,400	-18%	-$1.76M	1.69%	19
2021 Q1	$9.88M	Sell	609,531 -111,533	-15%	-$1.99M	2.58%	12
2020 Q4	$15.3M	Hold	721,064	–	–	5.02%	4
2020 Q3	$10.7M	Hold	721,064	–	–	2.42%	9
2020 Q2	$10.6M	Sell	721,064 -56,535	-7%	-$929K	2.39%	9
2020 Q1	$9.13M	Sell	777,599 -420,000	-35%	-$7.89M	1.72%	10
2019 Q4	$28.1M	Sell	1,197,599 -314,382	-21%	-$6.96M	2.14%	11
2019 Q3	$28M	Buy	+1,511,981	New	+$27.8M	1.74%	13

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Nexpoint Asset Management's HRTX Position: Q2 2026 in Review

Nexpoint Asset Management held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 475,750 shares worth $203K. The position accounts for 0.01% of the portfolio, ranked #67.

Nexpoint Asset Management first reported a position in HRTX in Q3 2019 and has held it in 28 quarters since. The position peaked at $28.1M in Q4 2019. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Nexpoint Asset Management held 475,750 shares of Heron Therapeutics worth $203K as of Q2 2026.
Nexpoint Asset Management left its Heron Therapeutics share count unchanged in Q2 2026.
Heron Therapeutics made up 0.01% of Nexpoint Asset Management's portfolio in Q2 2026, its #67 holding.
Nexpoint Asset Management first reported a position in Heron Therapeutics in Q3 2019 and has held it in 28 quarters since.
Nexpoint Asset Management's Heron Therapeutics position peaked at $28.1M in Q4 2019.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Nexpoint Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.